An Impella device may represent a safer and effective alternative to ECMO for circulatory support in cardio-oncology patients with high bleeding risk.
Does an Impella device provide safer and effective circulatory support compared to ECMO in cardio-oncology patients with high bleeding risk?
Impella devices may offer a safer alternative to ECMO for circulatory support in cardio-oncology patients with high bleeding risk.
Absolute Event Rate: 0% vs 0%
Anthracycline-induced cardiotoxicity may be acute and unpredictable. In cardio-oncology patients with high bleeding risk, an Impella device may represent a safer and effective alternative to ECMO for circulatory support.
Aurigemma et al. (Sun,) reported a other. An Impella device may represent a safer and effective alternative to ECMO for circulatory support in cardio-oncology patients with high bleeding risk.